ethyl 4-hydroxy-2-(4-pyridyl)-1,3-thiazole-5-carboxylate | 190271-73-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 4-hydroxy-2-(4-pyridyl)-1,3-thiazole-5-carboxylate
• 英文别名: ethyl 4-hydroxy-2-(pyridin-4-yl)-1,3-thiazole-5-carboxylate；ethyl 4-hydroxy-2-(pyridin-4-yl)thiazole-5-carboxylate；ethyl 4-hydroxy-2-(4-pyridyl)-thiazole-5-carboxylate；ethyl 4-hydroxy-2-(4'-pyridinyl)-thiazole-5-carboxylate；ethyl 4-hydroxy-2-(pyridin-4-yl)-thiazole-5-carboxylate；Ethyl 4-hydroxy-2-(4-pyridyl)-thiazole-5-carboxylate；ethyl 4-hydroxy-2-pyridin-4-yl-1,3-thiazole-5-carboxylate
• CAS: 190271-73-9
• 化学式: C₁₁H₁₀N₂O₃S
• 分子量: 250.278
• InChiKey: SHVRAFGUKKOKIO-UHFFFAOYSA-N

物化性质

• 沸点：
  422.8±55.0 °C(Predicted)
• 密度：
  1.364±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-hydroxy-2-(4-pyridyl)-1,3-thiazole-5-carboxylate 在 吡啶 、 trans-bis(triphenylphosphine)palladium dichloride 、 sodium carbonate decahydrate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 ethyl 4-(2-chlorophenyl)-2-(pyridin-4-yl)thiazole-5-carboxylate
  参考文献：
  名称：

  Synthesis and structure–activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors

  摘要：

  The Cell division cycle 7 (Cdc7) protein kinase is essential for DNA replication and maintenance of genome stability. We systematically explored thiazole-based compounds as inhibitors of Cdc7 kinase activity in cancer cells. Our studies resulted in the identification of a potent, selective Cdc7 inhibitor that decreased phosphorylation of the direct substrate MCM2 in vitro and in vivo, and inhibited DNA synthesis and cell viability in vitro.

  DOI：

  10.1016/j.ejmech.2014.04.013
• 作为产物：
  描述：

  硫代异烟酰胺 、 溴代丙二酸二乙酯 在 吡啶 作用下， 以 甲苯 为溶剂， 以83.52%的产率得到ethyl 4-hydroxy-2-(4-pyridyl)-1,3-thiazole-5-carboxylate
  参考文献：
  名称：

  Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling

  摘要：

  探索旋转酶ATP酶平台，以定制新型抗结核药物前导。

  DOI：

  10.1039/c4ob02049a

文献信息

• Cycloalkyl tachykinin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US05750549A1

  公开（公告）日：1998-05-12

  The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.3, R.sup.6, R.sup.7, R.sup.8, R.sup.11, R.sup.12, R.sup.13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

  本发明涉及由结构式I表示的某些新化合物：##STR1##或其药学上可接受的盐，其中R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.11、R.sup.12、R.sup.13、A、Q、W、X、Y、Z和n在此处定义。本发明还涉及包含这些新化合物作为活性成分的药物配方，以及在治疗某些疾病中使用这些新化合物及其配方。本发明的化合物是催吐肽受体拮抗剂，可用于治疗炎症性疾病、疼痛或偏头痛、哮喘和呕吐。
• 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
  申请人：——

  公开号：US20030229068A1

  公开（公告）日：2003-12-11

  Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于治疗疾病，如细胞增殖或凋亡介导的疾病，具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的衍生物，药物组合物以及预防和治疗涉及中风、癌症等疾病和其他疾病或病症的方法。该发明还涉及制备这些化合物的方法，以及在这些方法中有用的中间体。
• Trpm8 antagonists
  申请人：Dompe' S.P.A.

  公开号：EP2606888A1

  公开（公告）日：2013-06-26

  The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula: Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.

  该发明涉及作为瞬时受体电位阳离子通道亚家族M成员8（TRPM8）的选择性拮抗剂的化合物，其化学式为：这些化合物在治疗与TRPM8活性相关的疾病方面具有用途，如疼痛、炎症、缺血、神经退行性疾病、中风、精神障碍、炎症性疾病和泌尿系统疾病。
• [EN] TRPM8 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPM8
  申请人：DOMPE SPA

  公开号：WO2013092711A1

  公开（公告）日：2013-06-27

  The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.

  该发明涉及作为Transient Receptor Potential阳离子通道亚家族M成员8 (TRPM8)的选择性拮抗剂的化合物，其化学式为(I)。所述化合物在治疗与TRPM8活性相关的疾病方面具有用途，如疼痛、炎症、缺血、神经退行性疾病、中风、精神障碍、瘙痒、肠易激综合征、冷诱导和/或加重的呼吸道疾病以及泌尿系统疾病。
• 2-(4'-Pyridinyl)-thiazole compounds and their use in increasing cardiac
  申请人：Schering Corporation

  公开号：US04528291A1

  公开（公告）日：1985-07-09

  The pyridinyl-thiazole derivatives of the present invention exhibit good cardiotonic activity.

  本发明中的吡啶基噻唑衍生物表现出良好的心脏强效活性。